Gramaticu Iulia Magdalena, Croitoru Adina Emilia
Chirurgia (Bucur). 2018 Nov-Dec;113(6):758-764. doi: 10.21614/chirurgia.113.6.758.
Gastric cancer is one the most common maligancies and a considerable health problem throughout the world. Multimodal approach, encompassing both radical surgery and perioperative chemotherapy provides the best chance to cure resectable gastric cancer. Data originating from well-conducted randomized trials demonstrate that chemotherapy improves survival in patients with metastatic disease. During the last years, two targeted therapies have been approved in metastatic setting. Based on promising clinical trials results, it is expected for the near future that immunotherapy to be incorporated in the multimodal treatment of gastric cancer.
胃癌是全球最常见的恶性肿瘤之一，也是一个相当严重的健康问题。包括根治性手术和围手术期化疗的多模式治疗方法为可切除胃癌的治愈提供了最佳机会。来自精心设计的随机试验的数据表明，化疗可提高转移性疾病患者的生存率。在过去几年中，两种靶向治疗已在转移性疾病的治疗中获得批准。基于有前景的临床试验结果，预计在不久的将来免疫疗法将被纳入胃癌的多模式治疗中。
